Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Copeptin and its potential role in diagnosis and prognosis of various diseases.

Dobsa L, Edozien KC.

Biochem Med (Zagreb). 2013;23(2):172-90. Review.

2.

The stress hormone copeptin: a new prognostic biomarker in acute illness.

Katan M, Christ-Crain M.

Swiss Med Wkly. 2010 Sep 24;140:w13101. doi: 10.4414/smw.2010.13101. Review.

PMID:
20872295
3.

Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology.

Bolignano D, Cabassi A, Fiaccadori E, Ghigo E, Pasquali R, Peracino A, Peri A, Plebani M, Santoro A, Settanni F, Zoccali C.

Clin Chem Lab Med. 2014 Oct;52(10):1447-56. doi: 10.1515/cclm-2014-0379. Review.

4.

Copeptin: clinical use of a new biomarker.

Morgenthaler NG, Struck J, Jochberger S, Dünser MW.

Trends Endocrinol Metab. 2008 Mar;19(2):43-9. doi: 10.1016/j.tem.2007.11.001.

PMID:
18291667
5.

Copeptin: a biomarker of cardiovascular and renal function.

Morgenthaler NG.

Congest Heart Fail. 2010 Jul;16 Suppl 1:S37-44. doi: 10.1111/j.1751-7133.2010.00177.x. Review.

6.

Prognostic Value of Copeptin in Chronic Kidney Disease: From General Population to End-Stage Renal Disease.

Golembiewska E, Machowska A, Stenvinkel P, Lindholm B.

Curr Protein Pept Sci. 2017;18(12):1232-1243. doi: 10.2174/1389203718666170717095301. Review.

PMID:
28714397
7.

[Copeptin - stable C-terminal fragment of pre-provasopressin as a new stress marker in newborns].

Jarosz-Lesz A, Maruniak-Chudek I.

Postepy Hig Med Dosw (Online). 2015 Jun 16;69:681-9. doi: 10.5604/17322693.1157421. Review. Polish.

8.

Copeptin and cardiovascular disease: a review of a novel neurohormone.

Yalta K, Yalta T, Sivri N, Yetkin E.

Int J Cardiol. 2013 Sep 1;167(5):1750-9. doi: 10.1016/j.ijcard.2012.12.039. Epub 2013 Jan 5. Review.

PMID:
23298558
9.

Copeptin: Pathophysiology and potential clinical impact.

Łukaszyk E, Małyszko J.

Adv Med Sci. 2015 Sep;60(2):335-41. doi: 10.1016/j.advms.2015.07.002. Epub 2015 Jul 17. Review.

PMID:
26233637
10.

Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects.

Szinnai G, Morgenthaler NG, Berneis K, Struck J, Müller B, Keller U, Christ-Crain M.

J Clin Endocrinol Metab. 2007 Oct;92(10):3973-8. Epub 2007 Jul 17.

PMID:
17635944
11.

Anterior and posterior pituitary function testing with simultaneous insulin tolerance test and a novel copeptin assay.

Katan M, Morgenthaler NG, Dixit KC, Rutishauser J, Brabant GE, Müller B, Christ-Crain M.

J Clin Endocrinol Metab. 2007 Jul;92(7):2640-3. Epub 2007 Apr 10.

PMID:
17426098
12.

Potential Clinical Utility of Copeptin (C-terminal provasopressin) measurements in clinical medicine.

Lewandowski KC, Brabant G.

Exp Clin Endocrinol Diabetes. 2016 Mar;124(3):173-7. doi: 10.1055/s-0035-1569341. Epub 2016 Mar 23. Review.

PMID:
27008633
13.

The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department.

Nickel CH, Bingisser R, Morgenthaler NG.

BMC Med. 2012 Jan 20;10:7. doi: 10.1186/1741-7015-10-7. Review.

14.

Copeptin: a new marker in cardiology.

Morawiec B, Kawecki D.

J Cardiovasc Med (Hagerstown). 2013 Jan;14(1):19-25. doi: 10.2459/JCM.0b013e3283590d59. Review.

PMID:
22964653
15.

Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin.

Morgenthaler NG, Struck J, Alonso C, Bergmann A.

Clin Chem. 2006 Jan;52(1):112-9. Epub 2005 Nov 3.

16.

Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study.

Maisel A, Xue Y, Shah K, Mueller C, Nowak R, Peacock WF, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand IS, Ng L, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Terracciano G, Kremastinos D, Hartmann O, von Haehling S, Bergmann A, Morgenthaler NG, Anker SD.

Circ Heart Fail. 2011 Sep;4(5):613-20. doi: 10.1161/CIRCHEARTFAILURE.110.960096. Epub 2011 Jul 15.

17.

Gender and renal function influence plasma levels of copeptin in healthy individuals.

Bhandari SS, Loke I, Davies JE, Squire IB, Struck J, Ng LL.

Clin Sci (Lond). 2009 Feb;116(3):257-63. doi: 10.1042/CS20080140.

PMID:
18647134
18.

Copeptin as a biomarker in heart failure.

Balling L, Gustafsson F.

Biomark Med. 2014;8(6):841-54. doi: 10.2217/bmm.14.50. Review.

PMID:
25224940
19.

Copeptin: a diagnostic factor for critical patients.

Yilman M, Erenler AK, Baydin A.

Eur Rev Med Pharmacol Sci. 2015 Aug;19(16):3030-6. Review.

20.

Copeptin: a new and promising diagnostic and prognostic marker.

Katan M, Müller B, Christ-Crain M.

Crit Care. 2008;12(2):117. doi: 10.1186/cc6799. Epub 2008 Mar 6.

Supplemental Content

Support Center